MGI Submits Saforis NDA: Pipeline To Propel Sales To $1 Bil. By 2010 – Firm
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
MGI Pharma’s recently submitted oral mucositis therapy Saforis and newly approved myelodysplastic syndromes agent Dacogen top a "deep and maturing pipeline" projected to drive corporate sales to $1 bil. by 2010, according the company.
You may also be interested in...
SuperGen Nixes Phase III For Orathecin Combination Use In Pancreatic Cancer
SuperGen is pulling the plug on plans for a randomized Phase III trial of its Orathecin combination therapy in first-line pancreatic cancer after a Phase II study fell short of a pre-specified threshold for median survival
Approvals In Brief
Pfizer's Chantix for smoking cessation: Labeling for Pfizer's newly approved selective nicotinic acetylcholine receptor partial agonist Chantix (varenicline) for smoking cessation includes superiority claims over GlaxoSmithKline's Zyban (bupropion). In one study, 44% of Chantix patients were abstinent in treatment weeks nine through 12 compared to 30% of Zyban patients and 17% on placebo, labeling says. Additionally, 29% of Chantix patients were continuously abstinent through the end of treatment compared to 23% of Zyban patients. On May 10, Chantix (formerly Champix) became the first nicotine agonist approved by FDA and the first new prescription medication approved for smoking cessation in nearly a decade. Roll-out of the tablet therapy is slated for the second half of the year...
SuperGen Nixes Phase III For Orathecin Combination Use In Pancreatic Cancer
SuperGen is pulling the plug on plans for a randomized Phase III trial of its Orathecin combination therapy in first-line pancreatic cancer after a Phase II study fell short of a pre-specified threshold for median survival